Notably, several PD-1/PD-L1 inhibitors, including pembrolizumab, nivolumab, or atezolizumab, are now approved for the treatment of recurrent or metastatic HNSCC and are being actively studied in combination with anti-angiogenic agents. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.